Literature DB >> 28817832

Successful Use of Grenz Rays for Disseminated Superficial Actinic Porokeratosis: Report of 8 Cases.

Egle Ramelyte1, Matilda Bylaite-Bucinskiene, Reinhard Dummer, Laurence Imhof.   

Abstract

BACKGROUND: Disseminated superficial actinic porokeratosis (DSAP) is a rare keratinization disorder with potential malignant transformation, for which present treatment strategies show limited success. AIM: To evaluate the response of DSAP lesions to grenz ray radiotherapy (RTx).
METHODS: Data of patients treated with RTx at University Hospital Zurich, Switzerland, between 2004 and 2015, were reviewed. Patients with DSAP, who received at least 1 RTx treatment session and who had been followed up for at least 4 weeks were included in the further data analysis.
RESULTS: The study cohort consisted of 8 patients with a median age of 73 years (range 54-84). All were treated with grenz rays for DSAP. Most (7/8) patients showed complete clinical clearing of the lesions. All patients experienced temporary side effects of RTx, which resolved within 4 weeks after the last irradiation.
CONCLUSION: We suggest radiotherapy with grenz rays as a treatment option for DSAP.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Disseminated superficial actinic porokeratosis; Grenz rays; Radiotherapy

Mesh:

Year:  2017        PMID: 28817832     DOI: 10.1159/000478855

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  2 in total

1.  The Effect of Hypoxia on Relative Biological Effectiveness and Oxygen Enhancement Ratio for Cells Irradiated with Grenz Rays.

Authors:  Chun-Chieh Chan; Fang-Hsin Chen; Kuang-Lung Hsueh; Ya-Yun Hsiao
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

2.  Management of disseminated superficial actinic porokeratosis and intraepidermal squamous cell carcinoma with low-dose radiation therapy.

Authors:  Fleur Kong; Tracy S Moreira-Lucas; Artur Kaminski; Lynda Spelman
Journal:  Australas J Dermatol       Date:  2021-05-06       Impact factor: 2.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.